CLS_B: Record Q2 sales and improved margins drive narrowed losses and strong growth outlook

About this update from Clinical Laserthermia Systems Ab Class B

Net sales rose 58% year-over-year for H1 2025, with Q2 sales at record levels and gross margin reaching 70%. Operating losses narrowed significantly, driven by strong neurosurgery segment growth and cost reductions. Long-term outlook remains robust.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Clinical Laserthermia Systems Ab Class B